Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial

Q: What type of study is this?

This is a Pre-Registered Trial study.

Neal D. Shore; Martin Gleave; Ugo De Giorgi; Antti Rannikko; Christopher Pieczonka; Swetha Sridharan; Klaus Brasso; Henry H. Woo; Antonio Gómez‐Caamaño; Jeff Saranchuk; Luke T. Nordquist; Ubirajara Ferreira; Yiyun Tang; Brad Rosbrook; Gabriel P. Haas; Matt Rosales; Fabian Zohren; Jamal Tarazi; Stephen J. Freedland

doi:10.1097/ju.0000000000004890

Key Points

To evaluate the efficacy of enzalutamide combined with leuprolide in treating high-risk biochemically recurrent prostate cancer.
Participants received enzalutamide alongside leuprolide treatment.
Secondary endpoints were assessed from the EMBARK trial.
The study focused on biochemical recurrence in prostate cancer patients.
Combination therapy improved outcomes related to biochemical recurrence.
Findings suggest potential benefits for high-risk patients receiving this treatment.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Trial shows that enzalutamide combined with leuprolide improves outcomes in high-risk prostate cancer patients, indicating potential for enhanced therapy.

Abstract

Nct02319837.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shore et al. (2025) studied this question.

synapsesocial.com/papers/69401d732d562116f28f9539 https://doi.org/10.1097/ju.0000000000004890

View Full Paper

Ask AI

Bookmark

Share

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading